Abstract:AbstractObjectiveThe overall survival (OS) of lung cancer patients has been significantly extended as a consequence of chemotherapy and targeted drug utilization, which has resulted in an increase in local recurrences. The present study followed patients to evaluate the short‐term and long‐term efficacies and the safety of high‐dose rate intraluminal brachytherapy (ILBT) in recurrent bronchogenic carcinoma patients, and investigate the factors that influence prognosis.MethodsThe clinical records, treatment, curable effects, and adverse events of 15 patients treated in the First Affiliated Hospital of Soochow University, Suzhou, China, who were diagnosed with recurrent bronchogenic cancer between 1 June 2009 and 30 September 2015 were reviewed, and survival analysis was assessed by the Kaplan–Meier method.ResultsA total of 15 recurrent bronchogenic carcinoma patients received ILBT, and information on curable effects and safety was available. The group consisted of two complete response (2/15), 11 partial response (11/15), one stable disease (1/15) and one progression disease (1/15). The response rate was 86.7% (13/15), and disease control (complete response + partial response + stable disease) was 93.3% (14/15). The dyspnea indexes of the patients decreased significantly in weeks 1, 2, 4, and 8 after ILBT treatment (P < 0.001). The average post‐ILBT partial remission period was 5.27 ± 3.35 months, and the median partial remission period was 3.24 months. The combination therapy of ILBT and bronchofiberscope (P = 0.013), and a total ILBT dose of ≥20 Gy could produce a partial effective rate. The progress‐free survival of patients was 9.5 months (95% CI 12.2–16.5 months), average progress‐free survival was 15.8 ± 14.4 months, median OS was 32.0 months (95% CI 25.0–30.0 months), 1‐year OS was 93.3% (14/15), and 3‐year OS was 40.0% (6/15). The main adverse events were bronchospasm and hemoptysis (grade III); others were grade I–II.ConclusionComputed tomography‐guided ILBT is a safe, effective palliative treatment for recurrent bronchogenic carcinoma, but it requires further study in larger groups.

Feasibility and Clinical Value of CT-guided (125)I Brachytherapy for Bilateral Lung Recurrences from Colorectal Carcinoma.

125I Brachytherapy of Locally Advanced Non-Small-cell Lung Cancer after One Cycle of First-Line Chemotherapy: a Comparison with Best Supportive Care.

Brachytherapy by Percutaneous Paracentesis Implantation of Iodine-125 Seeds for Lung Cancer

Computed Tomography Fluoroscopy-Guided Percutaneous 125I Seed Implantation for Safe, Effective and Real-Time Monitoring Radiotherapy of Inoperable Stage T1-3N0M0 Non-Small-cell Lung Cancer.

Brachytherapy by CT-guided Percutaneous Paracentesis Implantation of Iodine-125 Seeds for Lung Cancer

CT-guided 125I Brachytherapy on Pulmonary Metastases after Resection of Colorectal Cancer: A Report of Six Cases

CT-guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients.

125I Brachytherapy Combined with Chemotherapy of Advanced Non-Small Cell Lung Cancer

CT-guided Interstitial Brachytherapy of Inoperable Non-Small Cell Lung Cancer.

[CT Guided Radioactive 125I Seed Implantation in Treating Localized Advanced Pulmonary Carcinoma].

Computed Tomography‐guided Intraluminal Brachytherapy in Recurrent Bronchogenic Carcinoma: A Clinical Trial in a Small Group

Preliminary Clinical Efficacy of Iodine-125 Seed Implantation for the Treatment of Advanced Malignant Lung Tumors

(125) I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer after Progression of Concurrent Radiochemotherapy

Clinical efficacy of CT-guided ~(125)I seed implantation therapy for advanced lung cancer

CT-guided iodine-125 brachytherapy is an effective palliative treatment for the right lower paratracheal lymph nodes metastasis previously treatment failure

125 I Brachytherapy Combined with Chemotherapy for Patients with Inoperable Stage III Non-Small Cell Lung Cancer

CT-Guided 125 I Brachytherapy in the Treatment of Distant Metastases in the Oral Cavity and Maxillofacial Region

CT-guided percutaneous 125 I seed implantation brachytherapy in patients with stage Ⅲ non-small-cell lung cancer

Feasibility and clinical value of computed tomography-guided125I brachytherapy for pain palliation in patients with retroperitoneal lymph node metastases

CT-guided Permanent 125I Seed Interstitial Brachytherapy for Recurrent Retroperitoneal Lymph Node Metastases after External Beam Radiotherapy

Trans-Bronchoscope 125i Radioactive Seeds Implantation in Patients with Pulmonary Atelectasis Induced by Lung Cancer - A Pilot Study